Free Trial

Nutrien Ltd. (NYSE:NTR) Position Trimmed by ANTIPODES PARTNERS Ltd

Nutrien logo with Basic Materials background

ANTIPODES PARTNERS Ltd lowered its stake in shares of Nutrien Ltd. (NYSE:NTR - Free Report) by 21.4% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 807,845 shares of the company's stock after selling 219,447 shares during the quarter. Nutrien comprises about 1.3% of ANTIPODES PARTNERS Ltd's holdings, making the stock its 26th largest position. ANTIPODES PARTNERS Ltd owned 0.17% of Nutrien worth $40,129,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently modified their holdings of NTR. Allworth Financial LP increased its stake in shares of Nutrien by 117.1% during the 1st quarter. Allworth Financial LP now owns 938 shares of the company's stock valued at $50,000 after acquiring an additional 506 shares during the last quarter. GAMMA Investing LLC increased its position in Nutrien by 4,866.7% during the 1st quarter. GAMMA Investing LLC now owns 1,043 shares of the company's stock worth $52,000 after purchasing an additional 1,022 shares in the last quarter. Summit Securities Group LLC increased its position in Nutrien by 225.0% during the 4th quarter. Summit Securities Group LLC now owns 1,300 shares of the company's stock worth $58,000 after purchasing an additional 900 shares in the last quarter. HM Payson & Co. acquired a new stake in Nutrien during the 1st quarter worth approximately $65,000. Finally, Bessemer Group Inc. increased its position in Nutrien by 163.7% during the 1st quarter. Bessemer Group Inc. now owns 1,690 shares of the company's stock worth $84,000 after purchasing an additional 1,049 shares in the last quarter. Institutional investors and hedge funds own 63.10% of the company's stock.

Nutrien Stock Down 0.3%

Shares of NYSE:NTR traded down $0.20 during midday trading on Friday, reaching $60.09. The company had a trading volume of 986,871 shares, compared to its average volume of 1,838,592. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.22 and a quick ratio of 0.59. The stock's fifty day moving average price is $60.04 and its 200-day moving average price is $54.81. The stock has a market capitalization of $29.27 billion, a P/E ratio of 56.16, a PEG ratio of 1.09 and a beta of 0.80. Nutrien Ltd. has a one year low of $43.69 and a one year high of $65.08.

Nutrien (NYSE:NTR - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $0.11 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.35 by ($0.24). The company had revenue of $4.67 billion during the quarter, compared to the consensus estimate of $5.16 billion. Nutrien had a return on equity of 6.08% and a net margin of 2.05%. The firm's quarterly revenue was down 5.4% on a year-over-year basis. During the same quarter last year, the firm posted $0.46 EPS. Equities research analysts expect that Nutrien Ltd. will post 3.72 earnings per share for the current fiscal year.

Nutrien Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, July 18th. Shareholders of record on Monday, June 30th were paid a dividend of $0.545 per share. The ex-dividend date of this dividend was Monday, June 30th. This represents a $2.18 annualized dividend and a yield of 3.63%. Nutrien's payout ratio is 203.74%.

Analyst Upgrades and Downgrades

NTR has been the subject of a number of research analyst reports. Oppenheimer increased their target price on shares of Nutrien from $63.00 to $65.00 and gave the stock an "outperform" rating in a research report on Tuesday, July 15th. Barclays increased their target price on shares of Nutrien from $61.00 to $64.00 and gave the stock an "equal weight" rating in a research report on Monday, July 7th. Royal Bank Of Canada reissued an "outperform" rating on shares of Nutrien in a research report on Monday, July 14th. Morgan Stanley increased their target price on shares of Nutrien from $60.00 to $65.00 and gave the stock an "equal weight" rating in a research report on Thursday, June 26th. Finally, UBS Group upped their price target on Nutrien from $56.00 to $64.00 and gave the stock a "neutral" rating in a report on Wednesday. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $63.22.

Read Our Latest Research Report on NTR

About Nutrien

(Free Report)

Nutrien Ltd. provides crop inputs and services. The company operates through four segments: Retail, Potash, Nitrogen, and Phosphate. The Retail segment distributes crop nutrients, crop protection products, seeds, and merchandise products. The Potash segment provides granular and standard potash products.

Featured Articles

Institutional Ownership by Quarter for Nutrien (NYSE:NTR)

Should You Invest $1,000 in Nutrien Right Now?

Before you consider Nutrien, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nutrien wasn't on the list.

While Nutrien currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines